Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Yale University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Sherry McKee, Yale University
ClinicalTrials.gov Identifier:
NCT01730846
First received: November 9, 2012
Last updated: October 7, 2014
Last verified: October 2014
  Purpose

The purpose of this study is to examine whether doxazosin will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking daily smokers. Participants will participate in a smoking cessation attempt after the laboratory sessions.


Condition Intervention Phase
Smoking
Drug: Doxazosin
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Latency (min) to initiate ad-lib smoking session [ Time Frame: Lab Sessions (Day 20, 22) ] [ Designated as safety issue: No ]
    Latency to start smoking (min)


Secondary Outcome Measures:
  • Number of cigarettes smoked during ad-lib session [ Time Frame: Lab Sessions (Day 20, 22) ] [ Designated as safety issue: No ]
    Number of cigarettes smoking during ad-lib session

  • Days to first lapse during quit attempt [ Time Frame: 4-wk smoking cessation attempt ] [ Designated as safety issue: No ]
    Days to first instance of smoking (even a puff)

  • End of treatment 7-day point prevalence [ Time Frame: 4-wk smoking cessation attempt ] [ Designated as safety issue: No ]
    Smoking (yes/no) during Week 4 of cessation attempt


Estimated Enrollment: 60
Study Start Date: February 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Doxazosin
doxazosin 4mg/day doxazosin 8mg/day
Drug: Doxazosin

4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.

8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.

Other Name: Cardura
Placebo Comparator: Placebo
placebo control
Drug: Placebo
Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Ages 18-60
  • Able to read and write English
  • Smoker
  • Motivated to Quit Smoking

Exclusion Criteria:

  • Any significant current medical conditions that would contraindicate smoking
  • Current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) abuse or dependence of other substances, other than nicotine dependence or alcohol abuse
  • Positive test results at intake appointment on urine drug screens for illicit drugs
  • Past 30 day use of psychoactive drugs including anxiolytics and antidepressants
  • Women who are pregnant or nursing
  • Suicidal, homicidal or evidence of current severe mental illness such as schizophrenia, bipolar disorder or major depression, or anxiety disorders
  • Participants who have donated blood within the past 6 weeks
  • Individuals who are currently taking other medications prescribed for smoking cessation
  • Specific exclusions for administration of doxazosin or any alpha blocker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01730846

Contacts
Contact: Meaghan Lavery 203-737-2783 meaghan.lavery@yale.edu

Locations
United States, Connecticut
Yale Center for Clinical Investigations, Yale University Recruiting
New Haven, Connecticut, United States, 06519
Contact: Meaghan Lavery    203-737-2783    meaghan.lavery@yale.edu   
Principal Investigator: Sherry A McKee, PhD         
Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Sherry A McKee, PhD Yale University
  More Information

No publications provided

Responsible Party: Sherry McKee, Associate Professor of Psychiatry, Yale University
ClinicalTrials.gov Identifier: NCT01730846     History of Changes
Other Study ID Numbers: 1111009293, R21DA033597
Study First Received: November 9, 2012
Last Updated: October 7, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
smoking lapse behavior
smoking cessation
doxazosin
medication effect on smoking lapse behavior
medication effect on smoking cessation
stress

Additional relevant MeSH terms:
Doxazosin
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014